Intel Plunges 5.3% as ARK ETF Dumps Roblox, Buys Intellia
0h ago|5 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
intelark-invest
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. AiX is informational software — not investment advice. Past performance does not guarantee future results.
Cathie Wood’s ARK Invest purchased shares of Intellia Therapeutics and sold shares of Roblox, according to a report from investing.com published on August 25, 2026. The portfolio reallocation occurred against a backdrop of sharp declines for major technology stocks, with Intel Corporation shares trading at $87.26 as of 00:34 UTC today. That price represents a daily decline of 5.29%, with the stock trading in a range between $85.14 and $88.91 during the session. The single-day move underscores the volatility surrounding chipmaker equities as investors parse sector-specific demand signals.
ARK Invest’s public portfolio disclosures are closely tracked for signals on high-conviction thematic bets. The firm’s flagship ARK Innovation ETF has shifted its portfolio composition 47 times in the past quarter, reflecting an active management approach to disruptive technology sectors. The last major reallocation from a video game platform to a biotechnology name occurred in November 2025, when ARK reduced its Unity Software position to add to CRISPR Therapeutics.
The current macro backdrop is defined by the Federal Reserve’s benchmark interest rate holding at 4.75%, with the 10-year Treasury yield at 4.2%. Equity markets have exhibited sector rotation out of traditional technology hardware and into healthcare and utilities over the past month. The S&P 500 Information Technology Index declined 3.1% week-over-week, while the S&P 500 Health Care Index gained 0.8%.
The immediate catalyst for the Intel selloff appears to be a combination of the ARK trade report and broader sector sentiment. Semiconductor stocks have faced persistent headwinds from revised capital expenditure forecasts from major cloud providers. Amazon Web Services and Microsoft Azure both issued guidance for slower data center build-out growth in the second half of 2026. This directly pressures companies like Intel, which derive significant revenue from data center CPU sales.
Gene-editing stocks, including Intellia Therapeutics, have recently benefited from a clarified regulatory pathway. The U.S. Food and Drug Administration issued draft guidance on July 30, 2026, outlining a accelerated review process for in vivo CRISPR-based therapies targeting monogenic diseases. This regulatory clarity reduces development timeline uncertainty for Intellia’s lead candidate, NTLA-2001 for transthyretin amyloidosis.
The market data illustrates the pronounced single-day pressure on Intel. The stock’s 5.29% decline to $87.26 translates to a market capitalization loss of approximately $22.1 billion, based on its outstanding share count of 4.2 billion. The day’s trading range of $85.14 to $88.91 shows a volatility band of 4.3%, significantly wider than its 30-day average daily range of 2.1%. Trading volume for INTC reached 85 million shares, 220% of its 30-day average volume.
This performance starkly contrasts with broader market indices. The Nasdaq Composite Index declined 1.2% on the same session, while the Philadelphia Semiconductor Index fell 3.8%. Intel’s decline was 40% more severe than the median decline across the 30 components of the SOX index. The stock’s year-to-date performance is now -18%, compared to the SOX index’s year-to-date performance of -7%.
A comparison of key valuation metrics before and after the decline shows the compression in investor sentiment. Intel’s forward price-to-earnings ratio fell from 18.2 to 17.3 based on consensus 2027 earnings estimates of $5.04 per share. The stock’s price-to-sales ratio declined from 2.1 to 2.0, based on trailing twelve-month revenue of $183.5 billion. The dividend yield increased from 2.8% to 2.95% as the share price fell, with the quarterly dividend remaining at $0.125 per share.
Peer performance was mixed. Advanced Micro Devices shares declined 2.1% to $152.40. Nvidia shares fell 3.5% to $1,025.60. Taiwan Semiconductor Manufacturing Company’s U.S.-listed ADRs were down 1.8% at $142.15. This indicates the selling pressure was broad-based but most acute for companies with significant exposure to the traditional server CPU market, where Intel holds a dominant share.
The transaction signals a rotation within the disruptive technology theme from consumer-facing digital platforms to clinical-stage biotechnology. ARK’s sale of Roblox, a metaverse and gaming platform stock, likely reflects concerns over user growth monetization and rising platform development costs. Its purchase of Intellia represents a doubling-down on the precision medicine subtheme, where the firm already holds positions in CRISPR Therapeutics, Beam Therapeutics, and Editas Medicine.
Second-order effects include potential pressure on other video game and interactive media stocks. Electronic Arts shares declined 1.5% following the report. Take-Two Interactive Software shares fell 1.2%. Unity Software shares were down 2.8%. Biotechnology stocks in the gene-editing subsector saw modest gains. The iShares Biotechnology ETF rose 0.3%, while the SPDR S&P Biotech ETF was flat. Intellia’s direct peers, CRISPR Therapeutics and Editas Medicine, gained 1.1% and 0.8%, respectively.
A key limitation of interpreting this single trade is that ARK Invest manages multiple ETFs with overlapping holdings. The reported transaction could represent a rebalancing across different funds rather than a unified shift in firm-wide conviction. ARK’s total assets under management across all ETFs stand at $28.4 billion as of August 24, 2026. A single trade often represents less than 0.5% of a fund’s portfolio and may be part of routine portfolio management.
Positioning data from the options market shows increased bearish activity on Intel. Put option volume on INTC was 1.8 times its 20-day average, with the $85 strike put for September expiration seeing the largest volume increase. Call option volume on Intellia was 1.5 times its average, with the $45 strike call for October expiration attracting new buyers. The flow suggests some traders are positioning for continued weakness in semiconductors and a potential rebound in biotech volatility.
Intel’s next major catalyst is its third-quarter earnings report, scheduled for October 22, 2026. Investors will scrutinize the Data Center and AI segment revenue, which constituted 35% of total Q2 revenue. Guidance for the fourth quarter and full-year 2027 will be critical for sentiment. The key level to watch for INTC is the $85.14 intraday low from August 25, which now serves as immediate technical support. A sustained break below that level could trigger further selling toward the 200-week moving average at $82.40.
For Intellia Therapeutics, the next clinical catalyst is the release of 18-month data from the Phase 1 study of NTLA-2002 for hereditary angioedema, expected in Q4 2026. The company also plans to initiate a Phase 3 study for NTLA-2001 in early 2027, pending discussions with global regulators. The stock faces resistance near its 50-day moving average at $48.75. A close above that level on sustained volume could signal a breakout from its three-month consolidation range.
Market-wide, the next Federal Open Market Committee meeting on September 16-17, 2026, will provide updated interest rate projections. Any shift toward a more dovish stance could benefit growth-oriented stocks like those in ARK’s portfolios. The August Consumer Price Index report, due September 10, will also influence the rate outlook. For semiconductor equipment stocks, the SEMI industry association’s global equipment billings report for August, due September 18, will provide a read on capital spending trends.
ARK Invest’s trades are reported with a one-day delay and represent a snapshot of a actively managed portfolio. Retail investors should not interpret a single trade as an immediate signal to buy or sell. The firm’s investment thesis is long-term, focusing on a five-year horizon for disruptive innovation. Retail investors mimicking ARK’s trades face significant tracking error and transaction cost disadvantages. A more relevant consideration is the underlying sector themes of genomic revolution and digital entertainment, which have different risk-return profiles and correlation to interest rates.
AiX is our free MetaTrader 4 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. XAUUSD breakout engine.
Trade 800+ global stocks & ETFs
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.